Zura Bio Limited — FY2022 Form 10-K
Reporting-period caveat: The audited financial statements are for JATT Acquisition Corp, the pre-combination SPAC, for the year ended December 31, 2022. The business combination with Zura closed on March 20, 2023, after year-end. Accordingly, FY2022 results do not reflect Zura’s post-combination biotech operations.
Business context and reporting period
Before the combination, JATT had no operating business or revenue; its activities were formation, its 2021 IPO and the search for a business combination. Zura is a clinical-stage biotechnology company developing immune-mediated disease therapies. Its post-combination business and pipeline are described mainly in the proxy statement/prospectus incorporated by reference.
Key financial metrics
| Metric | FY2022 | Comparison period |
|---|---|---|
| Revenue | None | None |
| Net income | $3.55 million | $6.85 million for March 10–December 31, 2021 |
| Operating expenses | $2.68 million | $0.89 million for March 10–December 31, 2021 |
| Net cash used in operating activities | $1.07 million | $1.10 million for March 10–December 31, 2021 |
| Cash at year-end | $13,785 | $729,223 |
| Trust account investments | $141.47 million | $139.40 million |
| Current liabilities | $1.83 million | $0.27 million |
| Working capital | Deficit of approximately $1.8 million | Not clearly stated as a comparable figure |
FY2022 net income included $4.15 million of non-cash gains from changes in warrant-liability fair value and $2.08 million of trust-account investment income; it was not operating profit. Operating cash flow was negative, and no revenue or meaningful operating margin was reported. Year-end liabilities also included $4.01 million of deferred underwriting commissions and $1.92 million of warrant liabilities. The company reported no long-term debt obligations for JATT beyond disclosed agreements and loans.
Changes, transactions and liquidity
- Net income declined from the 2021 inception-period result, while general and administrative expense increased. The comparison period in 2021 was shorter than a full year.
- In January 2023 and at the March 2023 business-combination vote, shareholders redeemed 13,617,502 JATT shares for approximately $139.68 million. The filing reports approximately $1.90 million remaining in the trust account at March 20, 2023 after redemptions.
- At closing, the company received $20.10 million from a PIPE and $43.02 million from forward-purchase and redemption-backstop share purchases. The forward-purchase investors also received 2.5 million shares for no additional monetary consideration under the amended agreement.
- The combination provided $165 million of stated merger consideration to Legacy Zura securityholders, in shares and options. These transaction amounts are subsequent to FY2022 and should not be confused with year-end cash or operating performance.
- Zura repaid the Hydra note on March 21, 2023. The note had $8 million principal, 9% annual interest compounded daily, and was repaid for $10 million under a waiver arrangement.
Outlook, risks and unusual items
- The filing provides no financial guidance or quantified operating outlook. JATT had no operating revenues before the combination; Zura’s future operating results depend on development and commercialization of its licensed programs.
- Zura’s Pfizer anti-IL-7R license includes a $5 million upfront payment, up to $70 million in development and regulatory milestones, up to $525 million in sales milestones, and tiered royalties. The Lilly license includes a $7 million upfront payment, up to $158 million in development, regulatory and commercial milestones, up to $440 million in sales milestones, and royalties. These are potential contractual payments, not FY2022 expenses or guaranteed outcomes.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2022 due to a material weakness in accounting for complex financial instruments. Management said it performed additional analysis and planned remediation; the filing gives no assurance remediation will succeed.
- The independent auditor issued an unqualified opinion on the financial statements, but did not audit or opine on internal-control effectiveness.
- The filing identifies general risks, including uncertainty related to COVID-19 and the Russia-Ukraine conflict, whose specific financial effects were not determinable. Detailed Zura business risks are incorporated from the proxy statement/prospectus rather than restated here.
- No material legal proceedings were reported. The filing does not state a clear post-combination cash runway or a quantified forecast.
Investor verification priorities
- Review Zura’s subsequent-period financial statements for cash, burn rate, runway and the actual net proceeds retained after transaction costs and redemptions.
- Reconcile the reported closing financing, remaining trust cash, transaction expenses and Hydra repayment against post-combination cash and debt disclosures.
- Assess the material weakness, remediation progress and any later control deficiencies or financial-statement corrections.
- Review the incorporated proxy statement/prospectus for pipeline stage, clinical milestones, development costs, and the full risk factors and license terms.
- Check dilution from outstanding warrants, options, equity plans, registration rights and lock-up releases; the filing reports 27,552,148 shares, 6.9 million public warrants, 5.91 million private warrants and 1,941,933 options at closing.
- Verify apparent date and presentation inconsistencies in the filing text, including its reference to a Lilly equity grant agreement dated December 8, 2023 despite the reported March 2023 closing.